Selected bibliography (in order of publishing)

Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1.
Gullbo J, Wickström M, Tullberg M, Ehrsson H, Lewensohn R, Nygren P, Luthman K, Larsson R. J Drug Target. 2003 Jul;11(6):355-63. PMID: 14668056
https://www.ncbi.nlm.nih.gov/pubmed/14668056 

Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan.
Gullbo J, Dhar S, Luthman K, Ehrsson H, Lewensohn R, Nygren P, Larsson R. Anticancer Drugs. 2003 Sep;14(8):617-24. PMID: 14501383
http://www.ncbi.nlm.nih.gov/pubmed/14501383

Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.
Gullbo J, Lindhagen E, Bashir-Hassan S, Tullberg M, Ehrsson H, Lewensohn R, Nygren P, De La Torre M, Luthman K, Larsson R. Invest New Drugs. 2004 Nov;22(4):411-20.
https://www.ncbi.nlm.nih.gov/pubmed/15292711

The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo.
Wickström M, Johnsen JI, Ponthan F, Segerström L, Sveinbjörnsson B, Lindskog M, Lövborg H, Viktorsson K, Lewensohn R, Kogner P, Larsson R, Gullbo J. Mol Cancer Ther. 2007 Sep;6(9):2409-17. PMID: 17876040
https://www.ncbi.nlm.nih.gov/pubmed/17876040

The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro.
Wickström M, Haglund C, Lindman H, Nygren P, Larsson R, Gullbo J. Invest New Drugs. 2008 Jun;26(3):195-204. Epub 2007 Oct 6.
https://www.ncbi.nlm.nih.gov/pubmed/17922077

The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan.
Wickström M, Viktorsson K, Lundholm L, Aesoy R, Nygren H, Sooman L, Fryknäs M, Vogel LK, Lewensohn R, Larsson R, Gullbo J. Biochem Pharmacol. 2010 May 1;79(9):1281-90. doi: 10.1016/j.bcp.2009.12.022. Epub 2010 Jan 11. PMID: 20067771
http://www.ncbi.nlm.nih.gov/pubmed/20067771

Aminopeptidase N (CD13) as a target for cancer chemotherapy.
Wickström M, Larsson R, Nygren P, Gullbo J. Cancer Sci. 2011 Mar;102(3):501-8. doi: 10.1111/j.1349-7006.2010.01826.x. Epub 2011 Jan 30. Review. PMID: 21205077
http://www.ncbi.nlm.nih.gov/pubmed/21205077

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.
Chesi M, Matthews GM, Garbitt VM, Palmer SE, Shortt J, Lefebure M, Stewart AK, Johnstone RW, Bergsagel PL. Blood. 2012 Jul 12;120(2):376-85. doi: 10.1182/blood-2012-02-412783. Epub 2012 Mar 26. PMID: 22451422
http://www.ncbi.nlm.nih.gov/pubmed/22451422

In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.
Chauhan D, Ray A, Viktorsson K, Spira J, Paba-Prada C, Munshi N, Richardson P, Lewensohn R, Anderson KC. Clin Cancer Res. 2013 Jun 1;19(11):3019-31. doi: 10.1158/1078-0432.CCR-12-3752. Epub 2013 Apr 12. PMID: 23584492
http://www.ncbi.nlm.nih.gov/pubmed/23584492

The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo.
Strese S, Wickström M, Fuchs PF, Fryknäs M, Gerwins P, Dale T, Larsson R, Gullbo J. Biochem Pharmacol. 2013 Oct 1;86(7):888-95. doi: 10.1016/j.bcp.2013.07.026. Epub 2013 Aug 8. PMID: 23933387
http://www.ncbi.nlm.nih.gov/pubmed/23933387

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.
Berglund Å, Ullén A, Lisyanskaya A, Orlov S, Hagberg H, Tholander B, Lewensohn R, Nygren P, Spira J, Harmenberg J, Jerling M, Alvfors C, Ringbom M, Nordström E, Söderlind K, Gullbo J. Invest New Drugs. 2015 Dec;33(6):1232-41. doi: 10.1007/s10637-015-0299-2. Epub 2015 Nov 10. PMID: 26553306
http://www.ncbi.nlm.nih.gov/pubmed/26553306

Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma.
Viktorsson K, Shah CH, Juntti T, Hååg P, Zielinska-Chomej K, Sierakowiak A, Holmsten K, Tu J, Spira J, Kanter L, Lewensohn R, Ullén A.
Mol Oncol. 2016 Jan 2. pii: S1574-7891(15)00249-5. PMID: 26827254
http://www.ncbi.nlm.nih.gov/pubmed/26827254